Shane Olwill
Chief Development Officer Asgard Therapeutics
Shane Olwill serves as Chief Development Officer of Asgard Therapeutics. Shane joined Asgard from Pieris Pharmaceuticals, now merged with NASDAQ-listed Palvella Therapeutics, to lead IND-enabling studies and clinical trials planning for Asgard’s lead asset AT-108. During his thirteen years at Pieris, Shane played a pivotal role developing its diverse pipeline of clinical programs in immuno-oncology and respiratory diseases – progressing nine programs into the clinic. Prior to that he was Director of Research at AIM-listed Fusion Antibodies, building out its research team and establishing its technology platform. With over 60 intellectual property rights to his name, he is a recognized leader in drug development and a regular reviewer for prominent oncology and drug development journals.
Seminars
Highlighting the development of a new in vivo immune cell engineering modality for cancer immunotherapy, delivering differentiated therapeutic potential
Designing first-in-human clinical trial strategies for this novel approach, accelerating proof-of-concept while ensuring patient safety
Outlining future pipeline ambitions and long-term goals, driving sustained innovation and clinical impact
